AstraZeneca PLC DL-Notes 2012(12/42)
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
5.76
Yield spread Bundesanleihe
2.2574
Tradable for private investors
No
Minimum amount tradeable unit
2,000.00
Maturity
18/09/2042
Interest Rate
4.00 %
Currency
US Dollar
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE / YIELD | 82.435 G / 5.76 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 09:46:38 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 2.2574 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 82.435 | 82.18 |
| PREV. DAY'S PRICE | 82.051 | (07/24) |
| CHANGE DAY BEFORE | +0.38 | 0.47 % |
| 52 WEEK HIGH / LOW | 88.91 (10/28) | 81.69 (07/23) |
Master Data
| WKN | A1G9L5 |
| ISIN | US046353AG32 |
| SYMBOL | ZEGB |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | AstraZeneca PLC |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 4.00 % |
| INTEREST RUN FROM | 18/09/2012 |
| NEXT INTEREST PAYMENT | 18/09/2026 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 1.467 % |
| TRADING CURRENCY / NOTATION | US Dollar/ Percent |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 1.00 Bil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 2,000.00 |
| SMALLEST TRADEABLE UNIT | 1,000.00 |
| MATURITY | 18/09/2042 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Local currency bond: USD. Make Whole Call Option.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.